#GU15 - Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF) - Session Highlights

ORLANDO, FL, USA (UroToday.com) - One of the feared consequences of the recent United States Preventative Services Task Force’s Grade D recommendation against PSA-based screening for prostate cancer is that urologic oncologists would begin to see advanced disease similar to that of the pre-PSA era. Dr. Matthew Hall and colleagues presented data in an abstract that showed these fears may already be realized.

gucancerssympaltUsing the tumor registry data from the National Oncology Data Alliance, 87 500 patients were captured and classified by NCCN risk group. Frequencies were examined by date of diagnosis and grouped in six-month intervals, and linear regression was used to assess trends.

The study investigators found that percentage of men with PSA > 10 decreased from 2005-2011. Following the draft of the USPSTF statement in 2011, that proportion increased by 3% per year (p < 0.0004). Similarly, the proportion of men with intermediate risk or higher disease increased by 2.9% per year (p < 0.003). This trend seemed to affect septuagenarians the most, as the proportion of men > 75 years of age with PSA > 10 increased by double the rate of all other men from 2011-2013.

The authors concluded that with an estimated 233 000 new prostate cancer cases in 2014, approximately 14 000 men with low-risk cancer will shift to a higher-risk disease group.

Presented by Matthew David Hall, MD at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA

City of Hope, Duarte, CA USA

Reported by Nikhil Waingankar, MD, medical writer for UroToday.com


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.